Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6811 to 6825 of 8906 results

  1. Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

    Discontinued Reference number: GID-TA10566

    Technology appraisal guidance
    Discontinued

  2. Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer [TSID12065]

    In development Reference number: GID-TA11588 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. ALXN1840 for treating Wilson disease [ID6422]

    In development Reference number: GID-TA11449 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473

    In development Reference number: GID-TA11582 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099

    In development Reference number: GID-TA11640 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Cendakimab for treating eosinophilic oesophagitis in people 12 years TS ID 12088

    Discontinued Reference number: GID-TA11702

    Technology appraisal guidance
    Discontinued

  7. GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)

    Discontinued Reference number: GID-MT557

    Medical technologies guidance
    Discontinued

  8. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued Reference number: GID-MT563

    Medical technologies guidance
    Discontinued

  9. Evobrutinib for treating relapsing multiple sclerosis [ID6313]

    Discontinued Reference number: GID-TA11357

    Technology appraisal guidance
    Discontinued

  10. Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]

    In development Reference number: GID-TA11443 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]

    In development Reference number: GID-TA11166 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]

    In development Reference number: GID-TA11808 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]

    In development Reference number: GID-TA11690 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]

    In development Reference number: GID-TA11848 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

    Discontinued Reference number: GID-DT14

    Diagnostics guidance
    Discontinued